No Data
Express News | Alphamab Oncology - Interim Analysis of Phase II/III Clinical Trial of Kn026 Met Primary Endpoint of Pfs
Data from Corning Jerry's two dual-target ADC preclinical studies will be presented at the 2025 AACR Annual Meeting.
Suzhou, April 30, 2025 /PR Newswire/ -- Corning JieRui Biopharmaceuticals (Stock Code: 9966.HK) announced that the company presented clinical study data for two novel bispecific antibody-drug conjugates (ADCs), JSKN021 and JSKN022, in poster form at the 2025 Annual Meeting of the American Association for Cancer Research (AACR). This year's AACR annual meeting was held in Chicago, USA from April 25 to 30, 2025. Topic: JSKN021, a novel EGFR/HER3 dual-target bispecific antibody-drug conjugate, presents.
ALPHAMAB-B (09966.HK): Latest research results of JSKN021 and JSKN022 presented at the 2025 AACR Annual Meeting.
On April 30, Gelonghui reported that ALPHAMAB-B (09966.HK) announced that the latest results of preclinical studies for JSKN021 and JSKN022 were displayed during the poster presentation from April 25 to April 30, 2025, at the 2025 AACR Annual Meeting (the American Association for Cancer Research, one of the earliest and largest cancer research organizations dedicated to conquering cancer) (abstract presentation numbers: 5450 and 5451).
ALPHAMAB-B: 2024 Annual Report
ALPHAMAB-B (09966.HK) granted 0.05 million stock options and 0.49 million incentive shares.
On April 23, Gelonghui reported that ALPHAMAB-B (09966.HK) announced that on April 23, 2025, under the stock option plan following the initial public offering, the company has resolved to grant options to two eligible participants ("option grantees") (i.e., employees of the group) to subscribe for a maximum of 0.05 million shares of the company's ordinary shares with a par value of 0.000002 US dollars per share, subject to the acceptance by the option grantees. According to the restricted share award plan, the company has resolved to grant a total of 0.49 million shares as awards to five eligible participants ("award grantees") (i.e., employees of the group).
Hong Kong stocks fluctuated | Pharmaceutical stocks generally declined as the Trump administration launched an investigation into pharmaceuticals, but Institutions remain Bullish on the growth potential of Innovative Drugs.
Pharmaceutical stocks generally fell. As of the time of writing, ASCLETIS-B (01672) dropped 12.64%, trading at 5.46 Hong Kong dollars; ALPHAMAB-B (09966) fell 7.74%, trading at 6.44 Hong Kong dollars; HBM HOLDINGS-B (02142) decreased by 7.31%, trading at 7.1 Hong Kong dollars.
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
